Narrow search
Showing 1 - 10 of 77
Cover Image
Have newer cardiovascular drugs reduced hospitalization? : evidence from longitudinal country-level data on 20 OECD countries, 1995 - 2003
Lichtenberg, Frank R. - In: Health economics 18 (2009) 5, pp. 519-534
Persistent link: https://www.econbiz.de/10003845298
Cover Image
Have Newer Cardiovascular Drugs Reduced Hospitalization? Evidence from Longitudinal Country-Level Data on 20 OECD Countries, 1995-2003
Lichtenberg, Frank R. - 2010
This study examines the effect of changes in the vintage distribution of cardiovascular system drugs on hospitalization and mortality due to cardiovascular disease using longitudinal country-level data. The vintage of a drug is the first year in which it was marketed anywhere in the world. We...
Persistent link: https://www.econbiz.de/10012759312
Cover Image
Have Newer Cardiovascular Drugs Reduced Hospitalization? Evidence From Longitudinal Country-Level Data on 20 OECD Countries, 1995-2003
Lichtenberg, Frank R. - 2008
Countries with larger increases in the share of cardiovascular drug doses that contained post-1990 or post-1995 ingredients had smaller increases in the cardiovascular disease hospital discharge rate, controlling for the quantity of cardiovascular medications consumed per person, the use of...
Persistent link: https://www.econbiz.de/10012464639
Cover Image
Pharmaceutical Innovation and Cancer Survival
Lichtenberg, Frank R.; Jonsson, Bengt; Wilking, Nils - 2014
, expected survival, number of people diagnosed, and innovation in diagnostic, radiation, and surgical procedures. We find that …
Persistent link: https://www.econbiz.de/10014049989
Cover Image
Has medical innovation reduced cancer mortality?
Lichtenberg, Frank R. - In: CESifo economic studies : CESifo, a joint initiative of … 60 (2014) 1, pp. 135-177
I analyze the effects of four types of medical innovation and cancer incidence on US cancer mortality rates during the … pre‐dated factors that drove both innovation and mortality and that there would have been parallel trends in mortality in … the absence of innovation, the estimates indicate that there were three major sources of the 13.8% decline of the age …
Persistent link: https://www.econbiz.de/10010466909
Cover Image
The impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, 1997 - 2010 : evidence from longitudinal, disease-level data
Lichtenberg, Frank R.; Pettersson, Billie - In: Economics of innovation and new technology 23 (2014) 3/4, pp. 239-273
Persistent link: https://www.econbiz.de/10010407486
Cover Image
The impact of pharmaceutical innovation on cancer mortality in Belgium : 2004-2012
Lichtenberg, Frank R. - In: Forum for health economics & policy : an evolving … 20 (2017) 1, pp. 1-28
Persistent link: https://www.econbiz.de/10011701670
Cover Image
The impact of new drug launches on longevity growth in nine Middle Eastern and African countries, 2007-2015
Lichtenberg, Frank R. - In: Review of Middle East economics and finance 14 (2018) 3, pp. 1-15
Persistent link: https://www.econbiz.de/10011964261
Cover Image
The impact of biopharmaceutical innovation on disability, social security recipiency, and use of medical care of U.S. community residents, 1998-2015
Lichtenberg, Frank R. - In: Forum for health economics & policy : an evolving … 24 (2021) 1, pp. 35-74
Persistent link: https://www.econbiz.de/10013556762
Cover Image
The impact of pharmaceutical innovation on cancer mortality in Mexico, 2003-2013
Lichtenberg, Frank R. - In: Latin American Economic Review 26 (2017) 1, pp. 1-22
I assess the impact that pharmaceutical innovation had on cancer mortality in Mexico during the period 2003-2013, by ….) that were subject to more pharmaceutical innovation, controlling for changes in the age-standardized cancer incidence rate … of cancer drug innovation to Mexican longevity growth has been valuable, but, perhaps, it could have been even larger …
Persistent link: https://www.econbiz.de/10011994326